ÇOCUKLUK ÇAĞI AKUT MYELOBLASTİK LÖSEMİLERDE KAN ÜRÜNÜ KULLANIMININ KEMOTERAPİ BLOKLARINA GÖRE DAĞILIMI

Abstract

Aim : This study evaluates the association of total erythrocyte, random platelet and apheresis platelet suspension given to children receiving chemotherapy (CT) blocks with a diagnosis of acute myeloblastic leukemia (AML) with the chemotherapy (CT) block the patient received in that period. Material and Methods: The transfusion need of a total of 146 patients followed with a diagnosis of AML were determined as erythrocyte, random platelet and platelet suspension as number and type in bags from the moment the patients were diagnosed to the period the treatment ended by entering the blood bank data base records. Results: The number of total per patient average erythrocyte use of a total of 37 patients during the process from the moment they were diagnosed to the period the treatment ended was 27 (100-102). Of the CT blocks, the block in which both erythrocyte and apheresis platelet use was the highest was Aie block. While the average per person erythrocyte use was 8 (2-20) in this block, apheresis platelet use was found as 8,5 (1-28). While the number of average per person random platelet use was 20 (7-139), the number of average per person random platelet use was as 27 (1-102) in the Maintenance block, which is the CT block in which the most random platelet was used. Conclusion: In children with AML, a great number of blood and blood product transfusions are needed during CT. The efficiency of these transfusions can depend on a great number of factors such as the type of acute leukemia, patient age, patient gender, the CT block the patient is receiving, the CT drugs the patient is receiving in that period and whether the patient has a clinical picture such as infection, sepsis, intense consumption coagulopathy during that period.